U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to ...

Pharmaceutical giant AbbVie said Thursday it has agreed to pay more than $10 billion to buy Waltham cancer drug maker ImmunoGen, in the largest acquisition of a Massachusetts company this year.

AbbVie needs to diversify its drug portfolio because of the loss of exclusive rights to Humira. The recent acquisition of ImmunoGen fills several needs and comes at an excellent time. The ...

The deal, which prices ImmunoGen's stock at a 95% premium, could boost AbbVie's plans to expand into cancer drugs as its top-selling product Humira faces fierce competition.

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere ...

AbbVie's share price reflected the concerns. However, AbbVie just announced two big acquisitions, spurring its stock to rebound somewhat. Is this Dividend King now a no-brainer buy?

ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.

AbbVie is entering 2024 with a foothold in the antibody-drug conjugate (ADC) field thanks to its late-2023 buyout of ImmunoGen worth more than $10 billion.

Is AbbVie a buy? The business seems poised for long-term growth, and the dividend is solid (even if growth slows a bit). So is the stock worth buying today?

AbbVie outperformed expectations, with Humira remaining the market leader with 98% share despite LOE and biosimilar headwinds. Read more on ABBV stock here.

AbbVie has sufficient resources and experience to push these over the finish line of approval and market them successfully. Is AbbVie stock still a buy? The secret is definitely out on AbbVie.